drugset / Trial / NCT05585931

Effect of TPN171H on Spermatogenesis

NCT05585931

Phase 1 Completed 18 enrolled Vigonvita Life Sciences
RandomizedCrossoverQuadruple-blindTreatment

Summary

This study is a phaseⅠstudy to determine the acute effects of TPN171H on semen function in healthy male subjects.

Timeline

Start
2022-11-15
Primary completion
2022-12-16
Completion
2022-12-16

Drugs

EvaluationDrugModalityDoseRoute
Subject TPN171H Unknown 10 mg Oral

Indications